Page last updated: 2024-11-06

cortivazol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cortivazol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66249
CHEMBL ID2105842
CHEBI ID135820
SCHEMBL ID4875
MeSH IDM0047799

Synonyms (37)

Synonym
nsc-80998
cortivazol
1110-40-3
D03594
cortivazol (usan)
cortivazolum [inn-latin]
cortivazol [usan:inn]
einecs 214-175-8
11beta,17alpha,21-trihydroxy-6,16alpha-dimethyl-2'-phenylpregna-2,4,6-trieno(3,2-c)pyrazol-20-one 21-acetate
2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 21-(acetyloxy)-11,17-dihydroxy-6,16-dimethyl-2'-phenyl-, (11beta,16alpha)-
nsc 80998
cortivasolo [dcit]
11beta,17,21-trihydroxy-6,16alpha-dimethyl-2'-phenyl-2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one 21-acetate
2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 11beta,17,21-trihydroxy-6,16alpha-dimethyl-2'-phenyl-, 21-acetate
corticoid
CHEBI:135820
ym183k0h63 ,
altim
unii-ym183k0h63
cortivasolo
CHEMBL2105842
cortivazol [mi]
2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one, 21-(acetyloxy)-11,17-dihydroxy-6,16-dimethyl-2'-phenyl-, (11.beta.,16.alpha.)-
cortivazol [who-dd]
cortivazol [mart.]
11.beta.,17,21-trihydroxy-6,16.alpha.-dimethyl-2'-phenyl-2'h-pregna-2,4,6-trieno(3,2-c)pyrazol-20-one 21-acetate
cortivazol [usan]
cortivazol [inn]
SCHEMBL4875
RKHQGWMMUURILY-UHRZLXHJSA-N
DTXSID40149442
11,17,21-trihydroxy-6,16-dimethyl-2-phenyl-2-pregna-2,4,6-trieno[3,2-c]pyrazol-20-one 21-acetate
DB13003
EX-A7287
Q2421270
[2-[(1s,2r,13s,14s,16r,17r,18s,20s)-17,20-dihydroxy-2,11,16,18-tetramethyl-7-phenyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9,11-tetraen-17-yl]-2-oxoethyl] acetate
AKOS040746721

Research Excerpts

Overview

Cortivazol (CVZ) is a unique, high potency synthetic glucocorticoid. Has a phenylpyrazol fused to the A-ring of the steroid nucleus and displays binding consistent with two or more sites in the cytosol.

ExcerptReferenceRelevance
"Cortivazol is a phenylpyrazolo glucocorticoid of high potency and unusual structure. "( Cortivazol mediated induction of glucocorticoid receptor messenger ribonucleic acid in wild-type and dexamethasone-resistant human leukemic (CEM) cells.
Ashraf, J; Chilton, D; Kunapuli, S; Thompson, EB, 1991
)
3.17
"Cortivazol (CVZ) is a unique, high potency synthetic glucocorticoid, which has a phenylpyrazol fused to the A-ring of the steroid nucleus and displays binding consistent with two or more sites in the cytosol from CEM C7 cells (a human acute lymphoblastic T-cell line)."( Two glucocorticoid binding sites on the human glucocorticoid receptor.
Srivastava, D; Thompson, EB, 1990
)
1

Effects

ExcerptReferenceRelevance
"Cortivazol has potent antileukemic activity in childhood ALL. "( Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
Kurylak, A; Styczynski, J; Wysocki, M,
)
1.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (23.53)18.7374
1990's13 (38.24)18.2507
2000's10 (29.41)29.6817
2010's3 (8.82)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.35 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (15.38%)5.53%
Reviews0 (0.00%)6.00%
Case Studies8 (20.51%)4.05%
Observational0 (0.00%)0.25%
Other25 (64.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Plantar Fasciitis Treatment: Double Blinded Randomized Control Study of the Efficacy of an Injection of Platelet Rich Plasma (PRP) Versus an Infiltration of Corticosteroids [NCT03857334]50 participants (Actual)Interventional2016-07-01Completed
A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache [NCT00804895]Phase 2/Phase 343 participants (Actual)Interventional2008-12-31Completed
Clinical Results After Medical Therapy Alone or Medical Therapy Associated With Lumbar Traction in the Treatment of Nerve Root Pain of Lumbar Disc Herniation With Disco-radicular Conflict [NCT02793440]412 participants (Anticipated)Interventional2013-12-02Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]